Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 520-532

  René, Patricia ^a   Le Gouill, Christian ^a   Pogozheva, Irina D ^b   Lee, Gary ^c   Mosberg, Henry I ^b   Farooqi, I Sadaf ^d   Valenzano, Kenneth J ^c   Bouvier, Michel ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Amicus Therapeutics   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 (4 FLUOROPHENYL) 2 [4 [4(NAPHTHALENE 1 YL)BUTYL] PIPERAZIN 1 YL] ETHYL] 4 METHYLPIPERAZINE; 2 (5 BROMO 2 METHOXYPHENETHYL) N [N [(1 ETHYLPIPERIDIN 4 YL)METHYL] CARBAMIMIDOYL] 3 FLUOROBENZAMIDE; 2 [2 (2 METHOXY 5 NITROBENZYLTHIO) PHENYL] 1,4,5,6 TETRAHYDROPYRIMIDINE; 3 [4 [2 (4 FLUOROPHENYL) 2 (4 METHYLPIPERAZIN 1 YL)ETHYL] PIPERAZIN 1 YL] 2 METHYL 1 PHENYLPROPAN 1 ONE; ANTIOBESITY AGENT; CHAPERONE; LIGAND; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; MUTANT PROTEIN; N [3 (2,4 DICHLOROPHENYL) 1 [4 [2 [(1 METHOXYPROPAN 2 YLAMINO)METHYL] PHENYL] PIPERAZIN 1 YL] 1 OXOPROPAN 2 YL] PROPIONAMIDE; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CENTRAL NERVOUS SYSTEM; CONFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FLOW CYTOMETRY; MOUSE; MUTANT; MUTATION; NONHUMAN; OBESITY; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; TARGET CELL;

AGE OF ONSET; ALPHA-MSH; ANIMALS; BINDING SITES; BRAIN; CELL MEMBRANE; CYCLIC AMP; ENDOCYTOSIS; HEK293 CELLS; HUMANS; KINETICS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION, MISSENSE; OBESITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN FOLDING; PROTEIN TRANSPORT; RECEPTOR, MELANOCORTIN, TYPE 4; TRANSFECTION;

EID: 78649594776     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.172098     Document Type: Article

References (41)

1. Arasasingham PN, Fotsch C, Ouyang X, Norman MH, Kelly MG, Stark KL, Karbon B, Hale C, Baumgartner JW, Zambrano M, et al. (2003) Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/ melanocortin receptor binding. J Med Chem 46:9-11. (Pubitemid 36043781)
2. Bernier V, Bichet DG, and Bouvier M (2004) Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol 4:528-533. (Pubitemid 40533016)
3. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperrière A, Brouard R, Bouvier M, et al. (2006) Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 17:232-243.
4. Chaki S, Oshida Y, Ogawa S, Funakoshi T, Shimazaki T, Okubo T, Nakazato A, and Okuyama S (2005) MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol Biochem Behav 82:621-626. (Pubitemid 43184037)
5. Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG, Marsh DJ, Forrest MJ, Gopal-Truter S, Fisher J, et al. (2000) Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 9:145-154.
6. 7]-alpha-melanocyte-stimulating hormone binding and signaling. J Biol Chem 282:21712-21719.
7. Cone RD (2005) Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571-578. (Pubitemid 40594196)
8. Conn PM and Janovick JA (2009) Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 299:137-145.
9. Conn PM, Ulloa-Aguirre A, Ito J, and Janovick JA (2007) G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev 59:225-250. (Pubitemid 47481435)
10. Dubern B, Clément K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B, and Tounian P (2001) Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. J Pediatr 139:204-209. (Pubitemid 32721705)
11. Fan ZC and Tao YX (2009) Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J Cell Mol Med 13:3268-3282.
12. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, and O'Rahilly S (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348:1085-1095. (Pubitemid 36337319)
13. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, and O'Rahilly S (2000) Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106:271-279. (Pubitemid 30483131)
14. Farooqi S and O'Rahilly S (2006) Genetics of obesity in humans. Endocr Rev 27:710-718.
15. Galandrin S, Oligny-LongpréG, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430.
16. Govaerts C, Srinivasan S, Shapiro A, Zhang S, Picard F, Clement K, Lubrano- Berthelier C, and Vaisse C (2005) Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function. Peptides 26:1909-1919. (Pubitemid 41354549)
17. Haskell-Luevano C, Cone RD, Monck EK, and Wan YP (2001) Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 40:6164-6179. (Pubitemid 32466321)
18. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131-141.
19. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
20. Janovick JA, Maya-Nunez G, and Conn PM (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87:3255-3262. (Pubitemid 34816374)
21. Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S, Bertrais S, Hercberg S, Basdevant A, Clement K, et al. (2006) Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 91:1811-1818.
22. Maguire MP, Dai M, and Vos TJ (2002), inventors; Millennium Pharmaceuticals, Inc., Maguire MP, Dai M, and Vos TJ, assignees. Melanocortin-4 receptor binding compounds and methods of use thereof. World patent WO02062766, 2002 Aug 15.
23. Morello JP, Salahpour A, Laperrière A, Bernier V, Arthus MF, Lonergan M, Petäjä- Repo U, Angers S, Morin D, Bichet DG, et al. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105:887-895.
24. Nijenhuis WA, Garner KM, van Rozen RJ, and Adan RA (2003) Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem 278:22939-22945.
25. Noorwez SM, Malhotra R, McDowell JH, Smith KA, Krebs MP, and Kaushal S (2004) Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem 279:16278-16284. (Pubitemid 38509322)
26. Petäjä-Repo UE, Hogue M, Bhalla S, Laperrière A, Morello JP, and Bouvier M (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J 21:1628-1637. (Pubitemid 34614619)
27. Pogozheva ID, Chai BX, Lomize AL, Fong TM, Weinberg DH, Nargund RP, Mulholland MW, Gantz I, and Mosberg HI (2005) Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists. Biochemistry 44:11329-11341.
28. Pontillo J, Marinkovic D, Tran JA, Arellano M, Fleck BA, Wen J, Tucci FC, Nelson J, Saunders J, Foster AC, et al. (2005a) Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 15:4615-4618. (Pubitemid 41253905)
29. Pontillo J, Tran JA, White NS, Arellano M, Fleck BA, Marinkovic D, Tucci FC, Saunders J, Foster AC, and Chen C (2005b) Structure-activity relationship studies on a series of cyclohexylpiperazines bearing a phanylacetamide as ligands of the human melanocortin-4 receptor. Bioorg Med Chem Lett 15:5237-5240. (Pubitemid 41463655)
30. Rajagopal S, Rajagopal K, and Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
31. Robben JH, Sze M, Knoers NV, and Deen PM (2007) Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 292:F253-F260.
32. Schöneberg T, Schulz A, Biebermann H, Hermsdorf T, Römpler H, and Sangkuhl K (2004) Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 104:173-206.
33. Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, Bakshi R, Palucki B, Weinberg DH, MacNeil T, et al. (2002) Design and pharmacology of N-[(3R)-1,2,3,4- tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl) - 2-[4-cyclohexyl-4- (1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2- oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 45:4589-4593.
34. Tan K, Pogozheva ID, Yeo GS, Hadaschik D, Keogh JM, Haskell-Leuvano C, O'Rahilly S, Mosberg HI, and Farooqi IS (2009) Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 150:114-125.
35. Tao YX (2005) Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 239:1-14.
36. Tarnow P, Schoneberg T, Krude H, Gruters A, and Biebermann H (2003) Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity. J Biol Chem 278:48666-48673.
37. Thompson MD, Percy ME, McIntyre Burnham W, and Cole DE (2008) G protein-coupled receptors disrupted in human genetic disease. Methods Mol Biol 448:109-137.
38. Vos TJ, Balani S, Blackburn C, Chau RW, Danca MD, Drabic SV, Farrer CA, Patane MA, Stroud SG, Yowe DL, et al. (2006) Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists. Bioorg Med Chem Lett 16:2302-2305.
39. Xiang Z, Litherland SA, Sorensen NB, Proneth B, Wood MS, Shaw AM, Millard WJ, and Haskell-Luevano C (2006) Pharmacological characterization of 40 humanmelanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist. Biochemistry 45:7277-7288.
40. Yang Y, Cai M, Chen M, Qu H, McPherson D, Hruby V, and Harmon CM (2009) Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling. Regul Pept 155:46-54.
41. Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, and O'Rahilly S (2003) Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 12:561-574.